Efficiently move to market & help patients with internal programs.
Technology validation & new market expansion through partnerships.
Partnering in neurodegenerative, lysosomal storage & autoimmune diseases; across small & large molecules, ASOs, AAVs & siRNAs.
Leptomeningeal carcinomatosis is typically a late complication with cancer that has poor prognosis and limited treatment options. Patients diagnosed with LC, without treatment, survival is 4 to 6 weeks, with treatment survival is 3-6 months.
EnClear is developing our EnTrega CSF Platform to help patients with LC by improving the distribution of chemotherapeutics to the areas of the CNS that need it most. Our 3 year goal is to reduce side effects and extend life while increasing access to therapy.
Huntington's, ALS & FTD
Neurodegenerative diseases have no cures and patients experience progressive degeneration and death of nerve cells.
EnClear is working with multiple partners to optimize dosage profiles of siRNA & ASO therapies to help patients suffering from neurodegenerative diseases.
LYSOSOMAL STORAGE DISORDERS
Gaucher, Hunters & Tay-Sachs
Lysosomal Storage disorders are inherited disorders and characterized by an abnormal build-up of toxic materials in the body’s cells as a result of enzyme deficiencies. The build-up in cells causes progressive degeneration. There are nearly 50 of these disorders and Gaucher's is the most common type.
EnClear is actively looking for partners and collaborators to improve the distribution and effectiveness of enzyme replacement therapies.
CNS AUTOIMMUNE & EPILEPSIES
Autoimmune Epilepsy (AE) & Lupus
The immune system functions to protect the body from foreign attack , but in autoimmune diseases, the immune system mistakenly attacks healthy cells. There are more than 80 autoimmune diseases including about 30 autoimmune disorders of the nervous system.
EnClear is both working with and actively looking for partners and collaborators to improve the distribution and effectiveness of ASO, AAV and traditional small molecules.